VNRX News & Events

VolitionRx announces the release of a new clinical study demonstrating the significant prognostic value of its Nu.Q Cancer Assay in newly diagnosed lung cancer patients, which could help clinicians identify patients' likely outcomes and personalize treatment selection accordingly. The clinical paper entitled "Prognostic value of circulating H3K27Me3-nucleosomes in newly diagnosed lung cancer patients: Real-world evidence" has been written in conjunction with researchers and clinicians at the Hospices Civils de Lyon, France's second largest university hospital system, and is currently under peer review. Dr Andrew Retter, Medical Consultant, Volition said: "We have worked closely with the Lyon team over several years to develop the strong scientific and clinical evidence to support the use of Nu.Q in the management of cancer patients. These results indicate that measuring methylated nucleosome biomarker levels with the Nu.Q test, at Non Small Cell Lung Cancer diagnosis, can provide valuable information about survival, progression-free survival and, crucially, enhance the identification of patients who may benefit from curative care"

VolitionRx announces a collaboration with Sysmex, a leader in global in vitro diagnostics, to optimize Volition's Nu.Q NETs H3.1 assay on the Sysmex platform.

VolitionRx announces that it has expanded its intellectual property portfolio by filing a strategic patent application covering the use of its proprietary Nu.Q technology in triaging and monitoring patients who are suspected of having contracted the Ebola virus. Ebola is a rare but severe illness in humans, with an average case fatality rate around 50%. The disease is characterized by a low white cell count, disseminated intravascular coagulation, immunosuppression and septic shock. Volition is looking to translate this technology into immediate field application. The company is actively inviting global health organizations, pharmaceutical developers, non-governmental organizations, and distribution partners to collaborate on field trials, manufacturing scale-up, and potential deployment of its LFT prototypes in outbreak zones.